MedTrace Logo

Zinc Sulfate for Human Papillomavirus (HPV)

NCT03404310 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-09-22

No results posted yet for this study

Summary

The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high risk HPV versus placebo.

Conditions

Interventions

DIETARY_SUPPLEMENT

Zinc Sulfate

Participant will take one 220mg tablet twice daily for three months.

OTHER

Placebo (Gelatin Tablet)

Participant will take one tablet twice daily for three months.

Sponsors & Collaborators

  • Spectrum Health Hospitals

    lead OTHER

Principal Investigators

  • Rebecca Prudnick, DO · Spectrum Health Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-24
Primary Completion
2019-06-28
Completion
2019-06-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03404310 on ClinicalTrials.gov